May 28, 2026

A Phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors

View Presentation

April 16, 2026

PHST001 combination with standard-of-care chemotherapy enhances macrophage-mediated elimination of tumor cells

View Presentation

April 16, 2026

Initial results from a Phase 1 study of PHST001, a macrophage activating anti-CD24 antibody, in patients with advanced/metastatic solid tumors

View Presentation

April 16, 2026

PHST001, a humanized anti-CD24 hIgG4 antibody, is effective against metastatic tumors and retains its anti-tumor activity in the presence of competing IgG

View Presentation

December 9, 2025

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

View Presentation

December 9, 2025

PHST001, a humanized anti-CD24 antibody, induces phagocytosis of human tumor cells in vitro and tumor clearance in vivo.

View Presentation

December 9, 2025

PHST001, a humanized anti-CD24 antibody, induces phagocytosis of ovarian tumor cells in vitro and inhibits their growth in vivo

View Presentation

December 9, 2025

Phase 1 study of PHST001, a humanized anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors

View Presentation

December 9, 2025

CD24 gene amplification associates with poor survival outcomes across cancer indications

View Presentation